Genome-wide characterization of dynamic DNA 5-hydroxymethylcytosine and TET2-related DNA demethylation during breast tumorigenesis

IF 4.8 2区 医学 Q1 GENETICS & HEREDITY Clinical Epigenetics Pub Date : 2024-09-11 DOI:10.1186/s13148-024-01726-7
Shuang-Ling Wu, Lin Yang, Changcai Huang, Qing Li, Chunhui Ma, Fang Yuan, Yinglin Zhou, Xiaoyue Wang, Wei-Min Tong, Yamei Niu, Feng Jin
{"title":"Genome-wide characterization of dynamic DNA 5-hydroxymethylcytosine and TET2-related DNA demethylation during breast tumorigenesis","authors":"Shuang-Ling Wu, Lin Yang, Changcai Huang, Qing Li, Chunhui Ma, Fang Yuan, Yinglin Zhou, Xiaoyue Wang, Wei-Min Tong, Yamei Niu, Feng Jin","doi":"10.1186/s13148-024-01726-7","DOIUrl":null,"url":null,"abstract":"Breast tumorigenesis is a complex and multistep process accompanied by both genetic and epigenetic dysregulation. In contrast to the extensive studies on DNA epigenetic modifications 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC) in malignant breast tumors, their roles in the early phases of breast tumorigenesis remain ambiguous. DNA 5hmC and 5mC exhibited a consistent and significant decrease from usual ductal hyperplasia to atypical ductal hyperplasia and subsequently to ductal carcinoma in situ (DCIS). However, 5hmC showed a modest increase in invasive ductal breast cancer compared to DCIS. Genomic analyses showed that the changes in 5hmC and 5mC levels occurred around the transcription start sites (TSSs), and the modification levels were strongly correlated with gene expression levels. Meanwhile, it was found that differentially hydroxymethylated regions (DhMRs) and differentially methylated regions (DMRs) were overlapped in the early phases and accompanied by the enrichment of active histone marks. In addition, TET2-related DNA demethylation was found to be involved in breast tumorigenesis, and four transcription factor binding sites (TFs: ESR1, FOXA1, GATA3, FOS) were enriched in TET2-related DhMRs/DMRs. Intriguingly, we also identified a certain number of common DhMRs between tumor samples and cell-free DNA (cfDNA). Our study reveals that dynamic changes in DNA 5hmC and 5mC play a vital role in propelling breast tumorigenesis. Both TFs and active histone marks are involved in TET2-related DNA demethylation. Concurrent changes in 5hmC signals in primary breast tumors and cfDNA may play a promising role in breast cancer screening.","PeriodicalId":10366,"journal":{"name":"Clinical Epigenetics","volume":"133 1","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epigenetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13148-024-01726-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Breast tumorigenesis is a complex and multistep process accompanied by both genetic and epigenetic dysregulation. In contrast to the extensive studies on DNA epigenetic modifications 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC) in malignant breast tumors, their roles in the early phases of breast tumorigenesis remain ambiguous. DNA 5hmC and 5mC exhibited a consistent and significant decrease from usual ductal hyperplasia to atypical ductal hyperplasia and subsequently to ductal carcinoma in situ (DCIS). However, 5hmC showed a modest increase in invasive ductal breast cancer compared to DCIS. Genomic analyses showed that the changes in 5hmC and 5mC levels occurred around the transcription start sites (TSSs), and the modification levels were strongly correlated with gene expression levels. Meanwhile, it was found that differentially hydroxymethylated regions (DhMRs) and differentially methylated regions (DMRs) were overlapped in the early phases and accompanied by the enrichment of active histone marks. In addition, TET2-related DNA demethylation was found to be involved in breast tumorigenesis, and four transcription factor binding sites (TFs: ESR1, FOXA1, GATA3, FOS) were enriched in TET2-related DhMRs/DMRs. Intriguingly, we also identified a certain number of common DhMRs between tumor samples and cell-free DNA (cfDNA). Our study reveals that dynamic changes in DNA 5hmC and 5mC play a vital role in propelling breast tumorigenesis. Both TFs and active histone marks are involved in TET2-related DNA demethylation. Concurrent changes in 5hmC signals in primary breast tumors and cfDNA may play a promising role in breast cancer screening.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺肿瘤发生过程中 DNA 5-hydroxymethylcytosine 和 TET2 相关 DNA 去甲基化的全基因组动态表征
乳腺肿瘤发生是一个复杂的多步骤过程,同时伴有遗传和表观遗传失调。与对恶性乳腺肿瘤中 DNA 表观遗传修饰 5-羟甲基胞嘧啶(5hmC)和 5-甲基胞嘧啶(5mC)的广泛研究相反,它们在乳腺肿瘤发生早期阶段的作用仍然不明确。从通常的导管增生到非典型导管增生,再到导管原位癌(DCIS),DNA 5hmC 和 5mC 呈现出一致且显著的下降趋势。然而,与 DCIS 相比,5hmC 在浸润性导管乳腺癌中略有增加。基因组分析表明,5hmC和5mC水平的变化发生在转录起始位点(TSS)周围,并且修饰水平与基因表达水平密切相关。同时,研究还发现,不同羟甲基化区域(DhMRs)和不同甲基化区域(DMRs)在早期阶段重叠,并伴随着活性组蛋白标记的富集。此外,我们还发现与 TET2 相关的 DNA 去甲基化参与了乳腺肿瘤的发生,并且在与 TET2 相关的 DhMRs/DMRs 中富集了四个转录因子结合位点(TFs:ESR1、FOXA1、GATA3、FOS)。有趣的是,我们还在肿瘤样本和无细胞 DNA(cfDNA)之间发现了一定数量的共同 DhMRs。我们的研究揭示了 DNA 5hmC 和 5mC 的动态变化在推动乳腺肿瘤发生中的重要作用。TF和活性组蛋白标记都参与了与TET2相关的DNA去甲基化。原发性乳腺肿瘤和 cfDNA 中 5hmC 信号的同时变化可能会在乳腺癌筛查中发挥重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
5.30%
发文量
150
期刊介绍: Clinical Epigenetics, the official journal of the Clinical Epigenetics Society, is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms in relation to human disease, diagnosis and therapy. Clinical trials and research in disease model organisms are particularly welcome.
期刊最新文献
Longitudinal maternal glycemia during pregnancy and placental epigenetic age acceleration. Vitrification affects the post-implantation development of mouse embryos by inducing DNA damage and epigenetic modifications. Age-related changes in DNA methylation in a sample of elderly Brazilians. miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting. Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1